- Home
- / Caribou Biosciences
Caribou Biosciences
Stock Price
$1.9
2024-10-29
Market Capitalization
$174.4 M
2024-10-29
Revenue
$11.2 M
FY, 2025
Caribou Biosciences Summary
Company Summary
- Overview
- Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company. It develops chRDNA, a technology for complex genome editing, and CAR-T, a cell therapy platform.
- Type
- Public
- Status
- Active
- Founded
- 2012
- HQ
- Berkeley, CA, US | view all locations
- Website
- https://www.cariboubio.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Barbara McClung, Chief Legal Officer and Corporate Secretary
Steve Kanner, Chief Scientific Officer
Tim Kelly, Chief Technology Officer
LocationsView all
1 location detected
Berkeley, CA HQ
United States
2929 Seventh Street
Caribou Biosciences Financials
Summary Financials
- Revenue (Q1, 2026)
- $2.4M
- Net income (Q1, 2026)
- ($25.1M)
- Cash (Q1, 2026)
- $12.1M
- EBIT (Q1, 2026)
- ($26.3M)
- Enterprise value
- $189.3M